<DOC>
	<DOCNO>NCT01095510</DOCNO>
	<brief_summary>The objective study evaluate : ( 1 ) dose response ( 2 ) pharmacokinetics ( PK ) pharmacodynamics ( PD ) intravenous ( IV ) administration CINRYZE treatment acute angioedema attack child 25 kg less 12 year age hereditary angioedema ( HAE ) ; ( 3 ) determine safety tolerability follow IV administration CINRYZE study population .</brief_summary>
	<brief_title>CINRYZE Treatment Hereditary Angioedema Attacks Children Under Age 12</brief_title>
	<detailed_description>Each subject receive CINRYZE treatment single acute angioedema attack .</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<criteria>To eligible protocol , subject must : 1 . Be least 10 kg body weight . 2 . Have confirm diagnosis HAE . 3 . Have acute HAE attack able initiate treatment within 8 hour onset symptom . To eligible protocol , subject must : 1 . Have active infectious illness . 2 . Have prior HAE attack and/or receive C1 INH product within 7 day prior dose study drug . 3 . Have receive therapy antifibrinolytics ( e.g. , tranexamic acid ) , androgens ( e.g. , danazol , oxandrolone , stanozolol , testosterone ) , ecallantide ( Kalbitor® ) , icatibant ( Firazyr® ) within 7 day prior dose study drug . 4 . Have history allergic reaction C1 INH product , include CINRYZE ( component CINRYZE ) , blood product . 5 . Have participate investigational drug evaluation within 30 day prior dose study drug , previously receive treatment CINRYZE study time .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>HAE</keyword>
	<keyword>CINRYZE</keyword>
	<keyword>C1 INH</keyword>
	<keyword>C1 inhibitor</keyword>
	<keyword>Pediatric</keyword>
	<keyword>PK/PD</keyword>
</DOC>